Mark Zuckerberg-backed group to spend $250 million on Chicago biotech hub; Intellia Therapeutics receives approval from FDA to start testing Crispr therapy; California couple accuses fertility clinic of mistakenly implanting an embryo that contained a genetic mutation for a rare cancer.
Five things for pharma marketers to know: Thursday, March 2, 2023
Concerns about prospects of COVID vaccine maker Novavax sink shares; House Republicans launch an investigation into PBMs; Amarin shareholders add seven Sarissa Capital nominees to its board, oust chairman.
Five things for pharma marketers to know: Wednesday, March 1, 2023
AI breakthrough from Alphabet’s DeepMind ‘changes scientific history’ and could lead to new cures; Adamis Pharmaceuticals announces merger agreement with DMK Pharmaceuticals; Theravance cut its JAK inhibitor along with 17% of its workforce.
Five things for pharma marketers to know: Tuesday, February 28, 2023
Billy Dunn to leave FDA; Irenic Capital urges Theravance to conduct review, add shareholder to board; FDA accepts SpringWorks Therapeutics’ nirogacestat NDA.
Five things for pharma marketers to know: Thursday, February 23, 2023
Apellis Pharmaceuticals to raise $300 million in stock and warrants offering; Mounjaro returns to shelves after a two-month shortage; Rubius Therapeutics closes up shop.
Five things for pharma marketers to know: Wednesday, February 22, 2023
Merck’s COVID-19 antiviral Lagevrio fails to prevent infection post-exposure; Actinium Pharmaceuticals’ antibody-radiation treatment iomab-B shows efficacy in Phase III trial; Public health experts voice concern over soda companies unveiling alcohol soda products.
Five things for pharma marketers to know: Tuesday, February 21, 2023
Biden administration sends medical experts to East Palestine in wake of train derailment; Pfizer drops half of participants after quality issues in Lyme disease trial; Kite CEO Christi Shaw to depart Gilead CAR-T unit.
Five things for pharma marketers to know: Friday, February 17, 2023
Sanofi, Astellas venture arms add cash to Avilar’s ‘ATAC’ mission; UNAids head warns that Big Pharma must value African lives above profits; West Pharmaceutical’s 2023 EPS guidance excludes consensus.
Five things for pharma marketers to know: Thursday, February 16, 2023
Amgen sees $56B in demand for mega bond deal; GSK faces renewed claims it knew about the cancer risks associated with Zantac; Bausch + Lomb names Brent Saunders as CEO.
Five things for pharma marketers to know: Wednesday, February 15, 2023
J&J talc unit faces bankruptcy judge after tactic rejected; GSK revises COVID-19 deal with Vir, pulls out of next-gen work; What to know about the deadly Marburg virus as new outbreak emerges.